Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 6-K

TRINITY BIOTECH PLC

SEC Filing

Filed Sep 9, 2026Accepted Sep 9, 2026, 8:35 AM EDTCIK 888721Accession 0001554855-26-001986
Share

Company context

We are a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. We develop, acquire, manufacture and market diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. We intend to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product.

Current securities

Recent company filings

  1. 6-K filingSep 8, 2026
  2. EFFECT filingSep 1, 2026
  3. 6-K filingAug 28, 2026
  4. POS AM filingAug 28, 2026
  5. AW filingAug 27, 2026

As-filed source

Primary evidence